6-hydroxy-2-(4-hydroxyphenyl)-4-vinylisoquinolin-1(2H)-one | 1042031-79-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 6-hydroxy-2-(4-hydroxyphenyl)-4-vinylisoquinolin-1(2H)-one
• 英文别名: 4-Ethenyl-6-hydroxy-2-(4-hydroxyphenyl)isoquinolin-1-one
• CAS: 1042031-79-7
• 化学式: C₁₇H₁₃NO₃
• 分子量: 279.295
• InChiKey: DEDJPVYPSZIEAL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  60.8
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-bromo-6-hydroxy-2-(4-hydroxyphenyl)-isoquinolin-1(2H)-one 、 乙烯硼酐吡啶络合物 在 四(三苯基膦)钯 potassium carbonate 作用下， 以 乙二醇二甲醚 为溶剂， 反应 4.0h， 以87%的产率得到6-hydroxy-2-(4-hydroxyphenyl)-4-vinylisoquinolin-1(2H)-one
  参考文献：
  名称：

  WO2008/91555

  摘要：

  公开号：

文献信息

• Nuclear receptor binding agents
  申请人：Dalton James T.

  公开号：US20090030036A1

  公开（公告）日：2009-01-29

  The present invention relates to a novel class of nuclear receptor binding agents (NRBAs). The NRBAs are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, inflammatory diseases, oxidative stress related disorders such as Parkinson's and stroke, neurological disorders, ophthalamic disorders, cardiovascular disease, and obesity.

  本发明涉及一种新型的核受体结合剂（NRBAs）。这些NRBAs适用于预防和/或治疗各种疾病和病症，包括预防和治疗癌症（如前列腺癌和乳腺癌）、骨质疏松症、激素相关疾病、炎症性疾病、氧化应激相关疾病（如帕金森病和中风）、神经系统疾病、眼科疾病、心血管疾病和肥胖症。
• NUCLEAR RECEPTOR BINDING AGENTS
  申请人：NARAYANAN Ramesh

  公开号：US20100267767A1

  公开（公告）日：2010-10-21

  The present invention relates to methods for prevention and/or treatment of metabolic disorders, post-menopausal obesity and conditions associated with high fat diet consumption including, obesity, body weight gain, fat mass formation, bone mineral content reduction, white adipose tissue weight gain, increased cholesterol levels, increased leptin levels, insulin resistance, type II diabetes, increased blood glucose levels, inflammatory diseases, cardiovascular diseases, fatty liver condition (accumulation of fat in the liver), decreased uncoupling protein-1 (UCP-1) levels and increased lipogenesis.

  本发明涉及预防和/或治疗代谢性疾病、绝经后肥胖和与高脂肪饮食摄入有关的状况，包括肥胖、体重增加、脂肪质量形成、骨矿物质含量降低、白色脂肪组织重量增加、胆固醇水平增加、瘦素水平增加、胰岛素抵抗、2型糖尿病、血糖水平增加、炎症性疾病、心血管疾病、脂肪肝病（肝脏脂肪积累）、UCP-1水平降低和脂肪合成增加的方法。
• ALDO-KETO REDUCTASE SUBFAMILY 1C3 (AKR1C3) INHIBITORS
  申请人：DALTON James T.

  公开号：US20130116277A1

  公开（公告）日：2013-05-09

  The present invention relates to a novel class of AKR1C3 inhibitors, to compositions containing them, to methods for their preparation, and to methods of use thereof. The AKR1C3 inhibitors may be useful in the treatment of, for example, prostate cancer, benign prostate hyperplasia (BPH), lung cancer, acne, seborrhea, hirsuitism, baldness, alopecia, precocious puberty, adrenal hypertrophy, polycystic ovary syndrome, breast cancer, uterine cancer, uterine fibroids, endometriosis, myeloma and leiomyoma.

  本发明涉及一种新型AKR1C3抑制剂类，包含其组成物，其制备方法以及使用方法。这些AKR1C3抑制剂可能在治疗前列腺癌、良性前列腺增生症（BPH）、肺癌、痤疮、皮脂溢出、多毛症、脱发、斑秃、性早熟、肾上腺增生、多囊卵巢综合症、乳腺癌、子宫癌、子宫肌瘤、子宫内膜异位症、骨髓瘤和平滑肌瘤的治疗中有用。
• US9078888B2
  申请人：——

  公开号：US9078888B2

  公开（公告）日：2015-07-14
• US9604931B2
  申请人：——

  公开号：US9604931B2

  公开（公告）日：2017-03-28